Abstract:Treating HIV is made difficult by the evolution of antimicrobial resistant mutants of that occurs in the life cycle of this virus. This has led to the evolution of numerous inhibition mechanism that intends to challenges the replication of this virus. One such approach is the application of molecular modelling in drug discovery. In this study the application of computer aided drug design were employed in finding an inhibitor that can contribute in finding a suitable drug candidate. Firstly, the ZINC database was screened using the Lipinski’s rule of five, and compounds having similar biological features were classified and grouped together into a compound library. Secondly, the co-crystallized structure of 1rv7 wild type of HIV-1 protease was used to construct a pharmacophore model that was used to screen further, the ZINC database Ligand stored in the compound library. Thestructure-basedpharmacophore was created by mimicking the three main active features of the co-crystallized structure from the Protein Data Bank, namely, 82 and 84, I50 and I150 residues.Thirdly, a total of twenty-six of the compounds that had less than 0,5 RMSD were identified and selected. Fourthly, based on the best docking ligands, ten of these compounds having high binding affinity were selected. These compounds are ZINC_001456687980 (-8.0), ZINC_001445792073 (-7.8) and ZINC_001461099137 (-7.4), successively. However, ZINC_001461099137 was eliminated based on unfavorable donor-donor interaction. The subsequent compound, ZINC_000015276352 was then placed on the top three leading compounds with a binding affinity of (-6.9). Fifthly, the ADMET property analysis was used on the top ten compounds, and the compounds that satisfied the analysis were, ZINC_001456687980, ZINC_000015276352, ZINC_001359888321 and ZINC_001460445290. The main properties that included the BBB permeation, the gastrointestinal absorption, pan assay interference structure (PAINS), were analyzed. ZINC_001456687980 had two violation (mw >350, XLOGP3>3.5),whiles ZINC_000015276352 had three violations (mw > 350, XLOGP3 > 3.5, rotatable > 7). Lastly, only two top compound underwent molecular dynamics simulations. Molecular dynamics simulation revealed the formation of numerous bond interactions between ZINC_001456687980 and ZINC_000015276352 together with the target protein.

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

3D-QSAR, Molecular Docking, and Molecular Dynamics Simulation of a Novel Thieno[3,4-D]pyrimidine Inhibitor Targeting Human Immunodeficiency Virus Type 1 Reverse Transcriptase

3D-QSAR for HIV-1 reverse transcriptase inhibitors

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods

Design, Synthesis and Evaluation of Novel HIV-1 NNRTIs with Dual Structural Conformations Targeting the Entrance Channel of the NNRTI Binding Pocket

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an in silico study

Receptor- and Ligand-Based 3D-QSAR Study for a Series of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of Non-Peptide Small Molecular Cxcr4 Antagonists As Anti-Hiv Agents: Recent Advances and Future Opportunities

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Identification of ZINC inhibitors for HIV-1 Protease through Structure-Based Pharmacophore, Virtual Screening, ADMET and Molecular Dynamics Simulation

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Design, Synthesis, and Antiviral Evaluation of Novel Hydrazone‐substituted Thiophene[3,2‐d]pyrimidine Derivatives As Potent Human Immunodeficiency Virus‐1 Inhibitors

An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors